Bioinvent/BI-1206 Maybe A Big Drug In The Future?
Contributor Since 2015
BI 1206
Description
BI 1206 is a so called antagonistic (blocking) antibody directed against the immunosuppressive target protein Fc gamma receptor IIb, CD32b. CD32b target protein is overexpressed on tumor cells in patients with lymphoma, particularly in those who respond poorly to the drugs available today. BI-1206 has a very interesting mechanism with the potential to be used both in the NHL and CLL, but also in other cancer indications. By the BI-1206 to block the immune-inhibitory effect of CD32b, the immune system is stimulated, which may enhance the therapeutic efficacy of rituximab as well as other antibody drugs.
Bioinvent says this
-Reduce Resistance problems
-Potential Market drug
-Has own cell killing effect against cancer
www.bioinvent.se/projects/projects/bi-1206/ For those who want to read more.
bioinvent.se/media/135181/capital-market...
Market
In Europe and North America gets annually about 157 000 people diagnosed with NHL, and about 35,000 people are diagnosed with chronic lymphocytic leukemia (CLL). The market for Non Hodgkins lyfom (NHL) was 6.6 billion USD in 2013 for CLL was 1.8 billion USD.
Where are BI-1206 now?
With the unique agreement with signed with Cancer resarch UK (cruk) and the related organizations CRT and LLR in January 2015 secured to a fully funded phase I/II study of patients in the NHL primarily CLL. value of this funded study is over 60 msek, it also gives Bioinvent access to a network of leading clinical and scientific experts in the UK The cooperation agreement gives BioInvent access to data from the study to the limited compensation in the form of milestone payments and royalties on future sales of an approved drug What I understood from the few analyzes available, it is about 5 million dollars and a future royalty around 2% to get access to data which is not very much.
The study is expected to take up to two years but is a so-called open label study, so you will receive ongoing results how the study unfolds. It is not yet what I understand decided whether it will use the BI-1206 alone or in combination with rituximab in this study, more info to come teach at baseline.
What's next for BI-1206?
The study will start in the second half of 2015 and will then continue into 2017, but with regular contact with Bioinvent during the study, so something interesting information should come in 2016 already. Among other things, they sought patent protection on nine major markets including the US, Europe, Japan and China. While the clinical study progress will preclinical studies continue, with a focus on showing the combined effects of BI-1206 and CD38 antibodies in multiple myeloma
Bioinvent published data from a preclinical study in Cancer cell at 13 april.
From the article "The researchers show that the novel antibody BI-1206, developed by BioInvent, has the ability to effectively prevent medicines this destructive process and improve the killing of cancer cells by binding to a molecule called FcgRIIB. In studies in mice have BI-1206 shown good results by overcoming resistance to monoclonal antibodies rituximab, a drug currently used to treat various types of lymphoma and leukemia. "
www.bioinvent.se/media-centre/press-rele...
www.eurekalert.org/pub_releases/2015-04/...
www.cell.com/cancer-cell/abstract/S1535-...
This says CRUK about it
Dr Emma Smith, senior science information officer at Cancer Research UK, said: "This exciting research has the potential to be a game-changer for people with white blood cell cancers that don't respond, or have stopped responding, to treatments like rituximab.
It could also make immunotherapy for other types of cancer more effective too. The work was carried out in mice, so we¿ll have to wait for the results from clinical trials to find out if the treatment is safe and effective in people, but it¿s certainly a promising approach and could lead to more potent drug combinations that benefit patients.
Sources
www.bioinvent.se/media/135181/capital-ma...
mb.cision.com/Main/583/9745864/359734.pdf
Disclosure: The author is long $BOVNF.